Universal genomic screening for cardiovascular disease

The challenge

Cardiovascular diseases are the leading cause of mortality globally, responsible for 18 million deaths per year.

Cardiovascular diagnosis and prognosis estimation today remain a challenge. Estimates are often inaccurate, time-consuming and many times invasive. General practitioners may fail to recognise the presence of increased risk of suffering a major cardiovascular event. Late diagnosis and inadequate prognosis decreases the chances for successful interventions creating financial and psychological strain for the patient, their families and their doctors. Cardiovascular science still trusts single biochemical markers such as cholesterol, but in the twenty-first century it is possible to know much more about the many alterations leading to atherosclerosis.

Our solution

We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect virtually any complex diseases, including cardiovascular disorders and cancer.

Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event.  Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.

This gives MultiplAI the power to:

• Offer a whole blood liquid biopsy screening test for cardiovascular diseases and other complex diseases.
• Reliably achieve high diagnostic accuracy
• Provide screening at a fraction of the cost of existing diagnosis options
• Predict prognosis and evaluate treatment results
• Administer testing anywhere you can safely extract a blood sample